Market

Market

Mild Cognitive Impairment (MCI)

Disease Information

Mild cognitive impairment (MCI) is a prevalent condition among aging adults that carries a high risk of progression to Alzheimer's disease or other dementias. MCI is characterized by memory impairment with otherwise unaffected cognitive functioning. A person with MCI experiences memory problems greater than normally expected with aging, but he or she does not show other symptoms of dementia, such as impaired judgment or reasoning. According to the Peripheral and Central Nervous System Drugs Advisory Committee, about 80% of patients with MCI develop Alzheimer's disease within six years. Accurate and early evaluation and treatment of MCI individuals might prevent further cognitive decline, including development of Alzheimer's disease (AD).

Symptoms

People suffering from MCI have sharp thinking and reasoning skills, but their long-term memory capabilities decline. Typically, people with the disorder have the most trouble remembering recently acquired information and knowledge (new memory consolidation), while their recall of past events may remain intact.

Causes

As with Alzheimer's disease, the causes of MCI remain unclear. No genetic link has yet been found for the condition, although it is possible that, like AD, genetic components might be risk factors for people with MCI to develop AD.

Diagnosis

The following medical tests may be used in diagnosis of MCI:

Along with medical tests and assessments, doctors rely on the following criteria to diagnose mild cognitive impairment:

Treatment

Although no treatment has been approved yet to prevent or manage mild cognitive impairment, its timely diagnosis can help delay the onset and progression of Alzheimer's disease. Because of the implied relationship, traditional treatment strategies for MCI thus far are based on those for AD. The FDA currently recommends acetylcholinestrase inhibitors (AchEI's).